 Hemophiliacs with symptomatic disease often receive blood products to correct clotting factor deficiencies. Prior to routine use of heat inactivation and screening of donor blood for specific viral pathogens, hemophiliacs were routinely exposed to, and infected with, viruses such as hepatitis B HBV, HCV, and HIV. Studies in hemophiliacs suggest several important findings that warrant further investigation, including: 1 hemophiliacs infected with HCV may have more rapid progression to liver failure and death; 2 pooled blood concentrate from multiple donors leads to a high risk of mixed infection; and 3 different clinical outcomes and altered immune responses of HIV coinfected hemophiliacs may enhance understanding of mutant virus selection and the associated clinical outcomes. The purpose of this trial is to determine response rates to PEG-interferon and ribavirin in hemophiliacs with HCV alone and with HCVHIV coinfection. 